Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Medtronic Plc.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Medtronic Plc
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
710 Medtronic Parkway Minneapolis, Minnesota 55432-5604
Telephone
Telephone
+1 (800) 633-8766
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Medtronic has acquired Intersect ENT's PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility.


Lead Product(s): Mometasone Furoate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Propel

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Intersect ENT

Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million

Deal Type: Acquisition May 13, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing.


Lead Product(s): Mometasone Furoate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Propel

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Intersect ENT

Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million

Deal Type: Acquisition August 06, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The 770G System is a first-of-a-kind device for patients aged 2 to 6 years. It is the first legally marketed device that can automatically adjust insulin delivery based on continuous glucose monitor values for this patient population.


Lead Product(s): Insulin

Therapeutic Area: Endocrinology Product Name: MiniMed 770G

Highest Development Status: ApprovedProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 01, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.


Lead Product(s): Insulin

Therapeutic Area: Endocrinology Product Name: MiniMed 780G

Highest Development Status: ApprovedProduct Type: Peptide

Partner/Sponsor/Collaborator: Blackstone Life Sciences

Deal Size: $337.0 million Upfront Cash: Undisclosed

Deal Type: Funding June 12, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY